Suvorexant, a new chemical entity intended for the treatment of insomnia, has been proposed for Schedule IV (79 Fed. Reg. 8639; Feb. 13, 2014). According to published reports, the drug is a novel, first in class, orexin receptor antagonist with a mechanism of action distinct from any marketed drug. It blocks wakefulness, rather than inducing sleep as do other sleep-aids. Suvorexan... Read More